Biocytogen
Beijing-based company providing genetically engineered and humanized mouse models with in vivo pharmacology services, especially for oncology and immunology antibody programs.
23 contract research organizations in our directory list at least one of Xenograft Models, Syngeneic Models, PDX Models, In Vivo Imaging, Orthotopic Tumor Models or Humanized Mouse Models, across 9 countries. 7 report GLP capability and 1 reports AAALAC accreditation. Compare their species, services and accreditations below, and contact labs directly from their profiles.
Preclinical oncology CROs test whether a cancer therapy shrinks or slows tumors in animal models, at doses that are tolerated and exposures that can be reached in patients. Most work is done in mice, and the choice of model follows from the mechanism of the drug.
Cell-line xenografts grow human tumor lines in immunodeficient mice and are fast, reproducible and inexpensive. Patient-derived xenografts (PDX) keep more of the original tumor biology and are used to test response across many tumors. Syngeneic models implant mouse tumors into mice with intact immune systems, which immuno-oncology agents need, and humanized mice carry human immune cells for agents that act only on human targets. Orthotopic and metastatic models, often tracked with bioluminescence imaging, place tumors in the relevant organ.
Standard endpoints are tumor volume over time, tumor growth inhibition and survival, usually with PK and biomarker sampling to link exposure to effect. Combination studies with standard-of-care agents are common, so ask whether the CRO has dosed those agents before and holds historical control data for them.
Showing 23 CROs. Order rotates daily so no lab is permanently listed first.
Beijing-based company providing genetically engineered and humanized mouse models with in vivo pharmacology services, especially for oncology and immunology antibody programs.
Wuhan CRO integrating NHP breeding with toxicity and safety evaluation, PK/PD, molecular imaging and bioanalysis.
Biomere (a JOINN company) is a preclinical CRO based in Worcester, MA. Services include non-GLP PK/PD, discovery toxicology, surgical services, disease models, and laboratory sciences. Surgical services include…
Chinese provider of genetically engineered mouse models with in vivo pharmacology services across oncology, immunology and metabolic disease.
French translational oncology CRO built around patient-derived xenograft models, with drug response and biomarker discovery services.
Translational testing and training laboratory in metro Atlanta supporting large animal preclinical device research, surgical models and procedural training.
Danish preclinical imaging CRO offering PET, SPECT, CT and MRI studies, radiopharmaceutical development support and oncology efficacy models.
Shanghai oncology CRO with patient-derived xenograft and other tumor models for efficacy studies.
Texas preclinical CRO offering xenograft and other oncology models, efficacy, pharmacology and toxicology studies.
Shanghai CRO centered on nonhuman primate efficacy and safety studies, with NHP disease models across metabolism, cardiovascular, renal, neurology and ophthalmology, clinical-style imaging and interventional surgery.
San Diego oncology CRO offering patient-derived and orthotopic tumor models for in vivo efficacy and translational studies.
Medical device focused CRO covering biocompatibility, preclinical surgical and interventional research, histopathology and regulatory consulting. Its Minneapolis preclinical site (formerly American Preclinical Services)…
Preclinical oncology and immuno-oncology CRO with orthotopic and metastatic models, whole-body imaging and GLP toxicology, with sites in Australia and the US.
Montreal-based neuroscience CRO combining neurodegenerative disease models with MRI imaging, quantitative neuropathology and image analysis.
Kentucky CRO developing immunodeficient rat and mouse models, offering xenograft efficacy and safety studies in larger rodent hosts.
Independent Danish CRO focused on early in vivo pharmacology in rodents, with particular expertise in mouse cancer and immuno-oncology models.
Lyon oncology CRO providing in vitro and in vivo proof-of-concept studies for anticancer agents, including resistant tumor models.
Small niche oncology pharmacology CRO validating in vivo efficacy of cancer therapies in clinically predictive models.
Minnesota company providing preclinical services and reagents for oncolytic virus, gene and cell therapy programs, including reporter imaging and efficacy models.
Spanish translational research center offering GLP and non-GLP large animal studies, device validation, advanced imaging and surgical training.
Nonprofit mouse genetics institute offering contract in vivo pharmacology using its own strains and humanized and PDX models across oncology, neuroscience, metabolism and immunology.
Berlin oncology CRO with a large collection of patient-derived xenograft models for in vivo efficacy and biomarker studies.
Israeli large animal CRO offering GLP and non-GLP surgical, interventional and imaging-supported studies for devices and therapeutics.